Search company, investor...
Parexel company logo


Founded Year



Incubator/Accelerator | Alive



About Parexel

Parexel provides biopharmaceutical services that include a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. It offers clinical data management, decentralized clinical trials, medical writing, medical monitoring and consulting, and other services. The company was founded in 1982 and is based in Newton, Massachusetts.

Headquarters Location

275 Grove Street Suite 101C

Newton, Massachusetts, 02466,

United States


Missing: Parexel's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Parexel's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Parexel

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Parexel in 1 CB Insights research brief, most recently on Dec 14, 2020.

Parexel Patents

Parexel has filed 13 patents.

The 3 most popular patent topics include:

  • Computational linguistics
  • Natural language processing
  • Artificial intelligence
patents chart

Application Date

Grant Date


Related Topics




Quebec provincial electoral districts, Database management systems, SQL, Data management, Databases


Application Date


Grant Date



Related Topics

Quebec provincial electoral districts, Database management systems, SQL, Data management, Databases



Latest Parexel News

MyEyeDr to collaborate with Parexel on clinical trial recruitment

Jan 25, 2023

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Clinical research organization Parexel announced an agreement with MyEyeDr. to refer its eye care patients into clinical trials. The two are collaborating on recruiting patients for a diabetic retinopathy study, according to a press release from Parexel, and plan to expand into other areas, such as endocrinology. Parexel and MyEyeDr. will work together on recruiting eye care patients into clinical trials. Source: Adobe Stock As part of the agreement, MyEyeDr. and its 850 eye care practices will be a member of Parexel’s Community Alliance Network, which helps bring clinical research into the community health care setting. Clare Grace Clare Grace, PhD, Paraxel’s chief patient officer, told Healio that the clinical research organization works with biopharma leaders, emerging innovators and sites to offer clinical research opportunities. “This formal agreement with MyEyeDr. will allow us to meet patients where they already are, such as centers providing annual routine eye exams and other vision care, to make clinical research more accessible,” Grace said. “The goal is that through this agreement, we will be able to generate an increased awareness of clinical research as a whole and within the optometry space to increase our reach for clinical trial recruitment and, ultimately, speed the availability of life-changing treatments for patients.” Artis Beatty, OD, MS, chief medical officer at MyEyeDr., told Healio that the group is working with Parexel on the diabetic retinopathy study to offer alternative treatment options to patients with specific diabetic eye disease. “Participating in the DREAM study has been a phenomenal way to open our relationship because of the number of patients that we actively manage and co-manage that meet the study criteria,” Beatty said. “We have been able to develop a number of systems for tracking and reporting for this particular study that will become the basis for future involvement with Parexel on any number of other ventures.” In addition, Beatty said MyEyeDr. can offer the benefits of a multisite entity. “All our practices operate on shared systems,” Beatty said. “That means ... millions of patients can decide to participate in research, be screened for participation criteria and reliably have records and reporting centralized in ways never before seen or imagined. This collaboration emphasizes the role optometrists play in primary patient care and the importance of that role in investigational medicine.” Grace added, “The ultimate goal of our agreement with MyEyeDr. is to make clinical research a more accessible care option by leveraging MyEyeDr.’s vast community of patients.” Reference: Parexel teams with MyEyeDr. to increase patient access and participation in ophthalmology clinical trials. . Posted Dec. 15, 2022. Accessed Jan. 24, 2023. Read more about

Parexel Frequently Asked Questions (FAQ)

  • When was Parexel founded?

    Parexel was founded in 1982.

  • Where is Parexel's headquarters?

    Parexel's headquarters is located at 275 Grove Street, Newton.

  • What is Parexel's latest funding round?

    Parexel's latest funding round is Incubator/Accelerator.

  • Who are the investors of Parexel?

    Investors of Parexel include ActiGraph Accelerant Partner Program, Goldman Sachs Asset Management, EQT Partners, Pamplona Capital Management, Boston Millennia Partners and 3 more.

  • Who are Parexel's competitors?

    Competitors of Parexel include Lindus Health and 2 more.

Compare Parexel to Competitors

Bitext Logo

Bitext is a company specialized in developing multilingual text analysis and NLP middleware to power large applications in CX platform, ML engines, and Chatbot platforms.

Castor EDC

Castor EDC specializes in electronic data capture for medical research. It aims to take the clinical trial process which it describes as largely being offline and paper-based and digitizes it via software.

Medable Logo

Medable is a decentralized clinical trial software company. The company's Software-as-a-Service (SaaS) cloud platform aims to provide a path to secure, HIPAA-compliant healthcare applications for researchers, startups, pharma, payers, and academia. This platform allows for supporting patient engagement clinical applications, storing personal health information, and complying with HIPAA and other regulations. Medable aims to enable patient-generated data to drive clinical research, healthcare delivery, and personalized and predictive medicine.

Curebase Logo

Curebase runs clinical trials via software that reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. Curebase was founded in 2017 and is based in San Francisco, California.

PhysIQ Logo

PhysIQ enables proactive care delivery models through its proprietary, FDA-cleared Personalized Physiology Analytics technology. PhysIQ offers a platform designed to process multiple vital signs from biosensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships, physIQ's analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health.

Innoplexus Logo

Innoplexus applies its proprietary tech stack in all stages of the drug development value chain via smart Data as a Service and Continuous Analytics as a Service solution. Generating insights from hundreds of Terabytes of structured and unstructured private and public data, Innoplexus helps organizations move towards continuous decision-making.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.